BioWorld

Oct. 15, 2018

Biopharma money raised: Jan. 1 - Oct. 11, 2018

Money raised by biopharma: 2018 vs. 2017

The week's biggest gainers and losers

BioWorld stock report for public biotechnology companies

Three quarters in, enthusiasm is high for biopharma deals in 2018, less so for M&As

Dealmaking for the biopharma industry has continued its steady climb through the third quarter of 2018, completing 18 percent more deals that in total are worth 25 percent more than they were this time last year. Read More

Nothing GAINed: Antimicrobial companies see their shares tumble

According to FDA Commissioner Scott Gottlieb, “the emergence of antibiotic resistance threatens the advances we’ve made in medicine.” Read More

Week in Washington

Phase II clinical trials: September 2018

Phase I clinical trials: September 2018

Phase III clinical trials: September 2018

Word on the street

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 17, 2024.

Second insulin receptor offers new therapeutic avenues

BioWorld Science

Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...

Mechanism underlying so-called idiopathic autism inception unveiled

BioWorld Science

Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic...

Drug duo to Repare lack in gyno cancers? Phase I shows promise

BioWorld

Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...